See more : Enigmo Inc. (3665.T) Income Statement Analysis – Financial Results
Complete financial analysis of RxSight, Inc. (RXST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RxSight, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- China Conch Environment Protection Holdings Limited (0587.HK) Income Statement Analysis – Financial Results
- Far East Bio-Tec Co., Ltd. (6886.TWO) Income Statement Analysis – Financial Results
- Exel Composites Oyj (EXL1V.HE) Income Statement Analysis – Financial Results
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Income Statement Analysis – Financial Results
- Capital A Berhad (AIABF) Income Statement Analysis – Financial Results
RxSight, Inc. (RXST)
About RxSight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 89.08M | 49.01M | 22.59M | 14.68M | 2.24M |
| Cost of Revenue | 35.31M | 27.68M | 18.08M | 12.97M | 4.06M |
| Gross Profit | 53.77M | 21.33M | 4.52M | 1.71M | -1.82M |
| Gross Profit Ratio | 60.36% | 43.52% | 19.99% | 11.62% | -81.17% |
| Research & Development | 29.05M | 25.98M | 24.50M | 21.93M | 29.57M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.80M | 58.67M | 32.81M | 15.18M | 15.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.85M | 84.65M | 57.30M | 37.11M | 44.77M |
| Cost & Expenses | 139.16M | 112.32M | 75.38M | 50.08M | 48.83M |
| Interest Income | 6.57M | 1.52M | 54.00K | 543.00K | 2.31M |
| Interest Expense | 3.31M | 4.95M | 3.68M | 510.00K | 26.00K |
| Depreciation & Amortization | 4.24M | 4.02M | 3.99M | 4.01M | 3.93M |
| EBITDA | -41.04M | -57.78M | -41.01M | 32.15M | 130.20M |
| EBITDA Ratio | -46.07% | -126.11% | -233.40% | -210.18% | -1,800.71% |
| Operating Income | -50.09M | -63.32M | -52.79M | -35.41M | -46.07M |
| Operating Income Ratio | -56.23% | -129.21% | -233.64% | -241.21% | -2,055.78% |
| Total Other Income/Expenses | 1.50M | -3.43M | 4.11M | 63.04M | 172.31M |
| Income Before Tax | -48.59M | -66.75M | -48.68M | 27.63M | 126.24M |
| Income Before Tax Ratio | -54.55% | -136.20% | -215.46% | 188.25% | 5,633.38% |
| Income Tax Expense | 20.00K | 9.00K | 8.00K | 57.00K | 24.00K |
| Net Income | -48.61M | -66.76M | -48.69M | 27.58M | 126.22M |
| Net Income Ratio | -54.57% | -136.22% | -215.50% | 187.87% | 5,632.31% |
| EPS | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| EPS Diluted | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| Weighted Avg Shares Out | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
| Weighted Avg Shares Out (Dil) | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
RxSight, Inc. (RXST) Q2 2023 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
RxSight, Inc. Reports Second Quarter 2023 Financial Results
RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023
Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?
RxSight, Inc. (RXST) Q1 2023 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. to Present at the Bank of America Healthcare Conference
RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023
Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy
Source: https://incomestatements.info
Category: Stock Reports